

Summary statistics - quantitative results

(Groups: manufacturer of instrument)

Filter: minimal size of groups n = 5

EQA round: IFT1/19 - Immunophenotypisation

Dead line: 15.04.2019

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Comparability							
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
(253) CD 3+ T lymphocytes					100							100	91	91%
Samples and groups	[%]													
Sample A		58,0	1,5	2,5	100	CVP	58	0,36	7%	53,9	62,1	100	95	95%
(12) Beckman Coulter		58,2	1,4	2,4	58	0						58		
(88) Becton Dickinson		57,3	1,9	3,3	37	0						37		
(177) MINDRAY		58,3	0,58	0,99	5	0						5		
Sample B		77,7	2,2	2,8	100	CVP	77,7	0,54	7%	72,2	83,2	100	96	96%
(12) Beckman Coulter		78,1	2,1	2,6	58	0						58		
(88) Becton Dickinson		77,2	2,6	3,4	37	0						37		
(177) MINDRAY		77,2	1,3	1,7	5	0						5		
(254) CD 4+ T lymphocytes					100							100	91	91%
Samples and groups	[%]													
Sample A		49,8	1,5	3,1	100	CVP	49,8	0,38	10%	44,8	54,8	100	93	93%
(12) Beckman Coulter		50,1	1,4	2,9	58	0						58		
(88) Becton Dickinson		49,1	1,9	4,0	37	0						37		
(177) MINDRAY		49,7	0,45	0,91	5	0						5		
Sample B		44,2	1,7	3,9	100	CVP	44,2	0,42	10%	39,7	48,7	100	96	96%
(12) Beckman Coulter		44,5	1,7	3,8	58	0						58		
(88) Becton Dickinson		43,8	2,2	5,0	37	0						37		
(177) MINDRAY		43,7	0,39	0,90	5	0						5		
(255) CD 8+ T lymphocytes					100							100	92	92%
Samples and groups	[%]													
Sample A		7,30	0,54	7,5	100	CVP	7,3	0,13	17%	6,05	8,55	100	92	92%
(12) Beckman Coulter		7,25	0,52	7,2	58	0						58		
(88) Becton Dickinson		7,37	0,50	6,8	37	0						37		
(177) MINDRAY		7,25	1,3	17	5	0						5		
Sample B		29,4	1,7	5,7	100	CVP	29,4	0,41	17%	24,4	34,4	100	99	99%
(12) Beckman Coulter		29,1	1,6	5,7	58	0						58		
(88) Becton Dickinson		30,0	1,8	6,1	37	0						37		
(177) MINDRAY		30,5	1,5	4,9	5	0						5		
(256) B lymphocytes					100							100	97	97%
Samples and groups	[%]													
Sample A		19,4	1,1	5,4	100	CVP	19,4	0,26	30%	13,5	25,3	100	99	99%
(12) Beckman Coulter		19,2	1,1	5,7	58	0						58		
(88) Becton Dickinson		19,8	0,97	4,9	37	0						37		
(177) MINDRAY		19,2	0,50	2,6	5	0						5		
Sample B		11,3	0,85	7,5	100	CVP	11,3	0,21	30%	7,91	14,7	100	97	97%
(12) Beckman Coulter		11,1	0,86	7,7	58	0						58		
(88) Becton Dickinson		11,5	0,83	7,2	37	0						37		
(177) MINDRAY		11,4	0,60	5,3	5	0						5		
(257) NK cells					100							100	90	90%
Samples and groups	[%]													
Sample A		21,1	1,5	7,2	100	CVP	21,1	0,37	26%	15,6	26,6	100	98	98%
(12) Beckman Coulter		21,0	1,4	6,7	58	0						58		
(88) Becton Dickinson		21,2	1,8	8,4	37	0						37		
(177) MINDRAY		20,6	0,42	2,1	5	0						5		
Sample B		9,54	1,3	14	100	CVP	9,54	0,32	26%	7,05	12,1	100	91	91%
(12) Beckman Coulter		9,60	1,2	13	58	0						58		
(88) Becton Dickinson		9,49	1,4	15	37	0						37		
(177) MINDRAY		9,29	1,0	11	5	0						5		

st_kn_p

End of report

Printed: 21.04.2019